Bayer/J&J Plan Rivaroxaban Filing For Chronic Indications In 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
An earlier filing for the oral factor Xa inhibitor is planned in the U.S. in 2008 for the prevention of venous thromboembolism.